BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gould Rothberg BE, Rimm DL. Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol 2010;130:1971-87. [PMID: 20555347 DOI: 10.1038/jid.2010.149] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Read J. Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment: Recent advances in cutaneous melanoma. Australasian Journal of Dermatology 2013;54:163-72. [DOI: 10.1111/ajd.12013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
2 Jayawardana K, Schramm SJ, Tembe V, Mueller S, Thompson JF, Scolyer RA, Mann GJ, Yang J. Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma. J Invest Dermatol 2016;136:245-54. [PMID: 26763444 DOI: 10.1038/JID.2015.355] [Cited by in Crossref: 52] [Cited by in F6Publishing: 31] [Article Influence: 8.7] [Reference Citation Analysis]
3 Tringali C, Silvestri I, Testa F, Baldassari P, Anastasia L, Mortarini R, Anichini A, López-Requena A, Tettamanti G, Venerando B. Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles. BMC Cancer 2014;14:560. [PMID: 25085576 DOI: 10.1186/1471-2407-14-560] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
4 Rexhepaj E, Agnarsdóttir M, Bergman J, Edqvist PH, Bergqvist M, Uhlén M, Gallagher WM, Lundberg E, Ponten F. A texture based pattern recognition approach to distinguish melanoma from non-melanoma cells in histopathological tissue microarray sections. PLoS One 2013;8:e62070. [PMID: 23690928 DOI: 10.1371/journal.pone.0062070] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
5 Ellis RA. T-type calcium channels as potential biomarkers in melanoma. Br J Dermatol 2017;176:1122. [PMID: 28504379 DOI: 10.1111/bjd.15472] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Rossi M, Tuck J, Kim O, Panova I, Symanowski J, Mahalingam M, Riker A, Alani R, Ryu B. Neuropilin-2 gene expression correlates with malignant progression in cutaneous melanoma. Br J Dermatol 2014;171:403-8. [DOI: 10.1111/bjd.12801] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
7 Cheng Y, Lu J, Chen G, Ardekani GS, Rotte A, Martinka M, Xu X, McElwee KJ, Zhang G, Zhou Y. Stage-specific prognostic biomarkers in melanoma. Oncotarget 2015;6:4180-9. [PMID: 25784655 DOI: 10.18632/oncotarget.2907] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
8 Tremante E, Ginebri A, Lo Monaco E, Frascione P, Di Filippo F, Terrenato I, Benevolo M, Mottolese M, Pescarmona E, Visca P, Natali PG, Giacomini P. Melanoma molecular classes and prognosis in the postgenomic era. Lancet Oncol 2012;13:e205-11. [PMID: 22554548 DOI: 10.1016/S1470-2045(12)70003-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
9 Vizkeleti L, Kiss T, Koroknai V, Ecsedi S, Papp O, Szasz I, Adany R, Balazs M. Altered integrin expression patterns shown by microarray in human cutaneous melanoma. Melanoma Res 2017;27:180-8. [PMID: 28234767 DOI: 10.1097/CMR.0000000000000322] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
10 Xu T, Gao H. Hydroxymethylation and tumors: can 5-hydroxymethylation be used as a marker for tumor diagnosis and treatment? Hum Genomics 2020;14:15. [PMID: 32375881 DOI: 10.1186/s40246-020-00265-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Schramm S, Menzies AM, Mann GJ. Molecular biomarkers of prognosis in melanoma: how far are we from the clinic? Melanoma Research 2013;23:423-5. [DOI: 10.1097/cmr.0000000000000001] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
12 Saldanha G, Joshi K, Lawes K, Bamford M, Moosa F, Teo KW, Pringle JH. 5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma. Mod Pathol 2017;30:60-8. [PMID: 27713424 DOI: 10.1038/modpathol.2016.159] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
13 Brunner G, Reitz M, Heinecke A, Lippold A, Berking C, Suter L, Atzpodien J. A nine-gene signature predicting clinical outcome in cutaneous melanoma. J Cancer Res Clin Oncol 2013;139:249-58. [DOI: 10.1007/s00432-012-1322-z] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
14 Gerami P, Gammon B, Murphy MJ. Melanocytic Neoplasms I: Molecular Diagnosis. In: Murphy MJ, editor. Molecular Diagnostics in Dermatology and Dermatopathology. Totowa: Humana Press; 2011. pp. 73-103. [DOI: 10.1007/978-1-60761-171-4_5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
15 Romaine ST, Wells-jordan P, de Haro T, Dave-thakrar A, North J, Pringle JH, Saldanha G. A small multimarker panel using simple immunohistochemistry methods is an adjunct to stage for cutaneous melanoma prognosis. Melanoma Research 2016;26:580-7. [DOI: 10.1097/cmr.0000000000000293] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
16 Rajabi P, Bagheri M, Hani M. Expression of Estrogen Receptor Alpha in Malignant Melanoma. Adv Biomed Res 2017;6:14. [PMID: 28299306 DOI: 10.4103/2277-9175.200789] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
17 Schramm SJ, Li SS, Jayaswal V, Fung DC, Campain AE, Pang CN, Scolyer RA, Yang YH, Mann GJ, Wilkins MR. Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden. Pigment Cell Melanoma Res 2013;26:708-22. [PMID: 23738911 DOI: 10.1111/pcmr.12126] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
18 Czyz M. Fibroblast Growth Factor Receptor Signaling in Skin Cancers. Cells 2019;8:E540. [PMID: 31167513 DOI: 10.3390/cells8060540] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
19 Cianfarani F, Mastroeni S, Odorisio T, Passarelli F, Cattani C, Mannooranparampil TJ, Fortes C, Failla CM. Expression of vascular endothelial growth factor-C in primary cutaneous melanoma predicts sentinel lymph node positivity. J Cutan Pathol. 2012;39:826-834. [PMID: 22804631 DOI: 10.1111/j.1600-0560.2012.01955.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
20 Kuźbicki Ł, Urban J, Chwirot BW. Different detectability of cyclooxygenase-2 (COX-2) protein in standard paraffin sections and tissue microarrays of human melanomas and naevi – Comparative study. Pathology - Research and Practice 2014;210:591-5. [DOI: 10.1016/j.prp.2014.04.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Franco R, Scognamiglio G, Salerno V, Sebastiani A, Cennamo G, Ascierto PA, Botti G, Turco MC, Rosati A. Expression of the anti-apoptotic protein BAG3 in human melanomas. J Invest Dermatol 2012;132:252-4. [PMID: 21850027 DOI: 10.1038/jid.2011.257] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
22 Wulfänger J, Schneider H, Wild P, Ikenberg K, Rodolfo M, Rivoltini L, Meyer S, Riemann D, Seliger B. Promoter methylation of aminopeptidase N/CD13 in malignant melanoma. Carcinogenesis 2012;33:781-90. [DOI: 10.1093/carcin/bgs091] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
23 Kemmerling R, Weyland D, Kiesslich T, Illig R, Klieser E, Jäger T, Dietze O, Neureiter D. Robust linear regression model of Ki-67 for mitotic rate in gastrointestinal stromal tumors. Oncol Lett 2014;7:745-9. [PMID: 24527082 DOI: 10.3892/ol.2014.1802] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
24 Wisco OJ, Sober AJ. Prognostic Factors for Melanoma. Dermatologic Clinics 2012;30:469-85. [DOI: 10.1016/j.det.2012.04.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
25 Weiss SA, Hanniford D, Hernando E, Osman I. Revisiting determinants of prognosis in cutaneous melanoma. Cancer 2015;121:4108-23. [PMID: 26308244 DOI: 10.1002/cncr.29634] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
26 Antonicelli F, Lorin J, Kurdykowski S, Gangloff SC, Le Naour R, Sallenave JM, Hornebeck W, Grange F, Bernard P. CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo. Br J Dermatol 2011;164:720-8. [PMID: 21155750 DOI: 10.1111/j.1365-2133.2010.10176.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
27 Mann GJ, Pupo GM, Campain AE, Carter CD, Schramm SJ, Pianova S, Gerega SK, De Silva C, Lai K, Wilmott JS, Synnott M, Hersey P, Kefford RF, Thompson JF, Yang YH, Scolyer RA. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol 2013;133:509-17. [PMID: 22931913 DOI: 10.1038/jid.2012.283] [Cited by in Crossref: 126] [Cited by in F6Publishing: 103] [Article Influence: 12.6] [Reference Citation Analysis]
28 Kaufman KL, Mactier S, Armstrong NJ, Mallawaaratchy D, Byrne SN, Haydu LE, Jakrot V, Thompson JF, Mann GJ, Scolyer RA, Christopherson RI. Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients. Clin Exp Metastasis 2014;31:407-21. [PMID: 24435119 DOI: 10.1007/s10585-014-9636-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
29 Vogelsang M, Wilson M, Kirchhoff T. Germline determinants of clinical outcome of cutaneous melanoma. Pigment Cell Melanoma Res 2016;29:15-26. [PMID: 26342156 DOI: 10.1111/pcmr.12418] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
30 Kuźbicki Ł, Lange D, Strączyńska-niemiec A, Chwirot BW. The value of cyclooxygenase-2 expression in differentiating between early melanomas and histopathologically difficult types of benign human skin lesions. Melanoma Research 2012;22:70-6. [DOI: 10.1097/cmr.0b013e32834defec] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
31 Verykiou S, Ellis RA, Lovat PE. Established and Emerging Biomarkers in Cutaneous Malignant Melanoma. Healthcare (Basel) 2014;2:60-73. [PMID: 27429260 DOI: 10.3390/healthcare2010060] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
32 Meyer S, Fuchs TJ, Bosserhoff AK, Hofstädter F, Pauer A, Roth V, Buhmann JM, Moll I, Anagnostou N, Brandner JM, Ikenberg K, Moch H, Landthaler M, Vogt T, Wild PJ. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS One 2012;7:e38222. [PMID: 22685558 DOI: 10.1371/journal.pone.0038222] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 5.2] [Reference Citation Analysis]
33 Ansari D, Rosendahl A, Elebro J, Andersson R. Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg. 2011;98:1041-1055. [PMID: 21644238 DOI: 10.1002/bjs.7574] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 6.7] [Reference Citation Analysis]
34 Butterfield LH, Potter DM, Kirkwood JM. Multiplex serum biomarker assessments: technical and biostatistical issues. J Transl Med 2011;9:173. [PMID: 21989127 DOI: 10.1186/1479-5876-9-173] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
35 Filimon A, Zurac SA, Milac AL, Sima LE, Petrescu SM, Negroiu G. Value of dopachrome tautomerase detection in the assessment of melanocytic tumors. Melanoma Res 2014;24:219-36. [PMID: 24709887 DOI: 10.1097/CMR.0000000000000066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]